Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis

References

1. 1.↵
   1. Ostrom QT,
   2. Patil N,
   3. Cioffi G, et al

   . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol 2020;22:iv1–96 doi:10.1093/neuonc/noaa200 pmid:33123732

   CrossRefPubMed
2. 2.↵
   1. Van Meir EG,
   2. Hadjipanayis CG,
   3. Norden AD, et al

   . Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60:166–93 doi:10.3322/caac.20069 pmid:20445000

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Lu-Emerson C,
   2. Duda DG,
   3. Emblem KE, et al

   . Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 2015;33:1197–213 doi:10.1200/JCO.2014.55.9575 pmid:25713439

   Abstract/FREE Full Text
4. 4.↵
   1. Chinot OL,
   2. Wick W,
   3. Mason W, et al

   . Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709–22 doi:10.1056/NEJMoa1308345 pmid:24552318

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Wick W,
   2. Gorlia T,
   3. Bendszus M, et al

   . Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 2017;377:1954–63 doi:10.1056/NEJMoa1707358 pmid:29141164

   CrossRefPubMed
6. 6.↵
   1. Gilbert MR,
   2. Dignam JJ,
   3. Armstrong TS, et al

   . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699–708 doi:10.1056/NEJMoa1308573 pmid:24552317

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Diaz RJ,
   2. Ali S,
   3. Qadir MG, et al

   . The role of bevacizumab in the treatment of glioblastoma. J Neurooncol 2017;133:455–67 doi:10.1007/s11060-017-2477-x pmid:28527008

   CrossRefPubMed
8. 8.↵
   1. Choi SH,
   2. Jung SC,
   3. Kim KW, et al

   . Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis. J Neurooncol 2016;128:185–94 doi:10.1007/s11060-016-2102-4 pmid:27108275

   CrossRefPubMed
9. 9.↵
   1. Pope WB,
   2. Qiao XJ,
   3. Kim HJ, et al

   . Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 2012;108:491–98 doi:10.1007/s11060-012-0847-y pmid:22426926

   CrossRefPubMed
10. 10.↵
    1. Rahman R,
    2. Hamdan A,
    3. Zweifler R, et al

    . Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol 2014;119:149–58 doi:10.1007/s11060-014-1464-8 pmid:24805151

    CrossRefPubMed
11. 11.↵
    1. Ellingson BM,
    2. Sahebjam S,
    3. Kim HJ, et al

    . Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. AJNR Am J Neuroradiol 2014;35:673–79 doi:10.3174/ajnr.A3748 pmid:24136647

    Abstract/FREE Full Text
12. 12.↵
    1. Ellingson BM,
    2. Gerstner ER,
    3. Smits M, et al

    . Diffusion MRI phenotypes predict overall survival benefit from anti-VEGF monotherapy in recurrent glioblastoma: converging evidence from phase II trials. Clin Cancer Res 2017;23:5745–56 doi:10.1158/1078-0432.CCR-16-2844 pmid:28655794

    Abstract/FREE Full Text
13. 13.↵
    1. Buemi F,
    2. Guzzardi G,
    3. Del Sette B, et al

    . Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme. Neuroradiol J 2019;32:241–49 doi:10.1177/1971400919847184 pmid:31066622

    CrossRefPubMed
14. 14.↵
    1. Schell M,
    2. Pflüger I,
    3. Brugnara G, et al

    . Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro Oncol 2020;22:1667–76 doi:10.1093/neuonc/noaa120 pmid:32393964

    CrossRefPubMed
15. 15.↵
    1. Pope WB,
    2. Kim HJ,
    3. Huo J, et al

    . Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182–89 doi:10.1148/radiol.2521081534 pmid:19561256

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Patel KS,
    2. Everson RG,
    3. Yao J, et al

    . Diffusion magnetic resonance imaging phenotypes predict overall survival benefit from bevacizumab or surgery in recurrent glioblastoma with large tumor burden. Neurosurg 2020;87:931–38 doi:10.1093/neuros/nyaa135 pmid:32365185

    CrossRefPubMed
17. 17.↵
    1. Park JE,
    2. Kim HS,
    3. Park SY, et al

    . Identification of early response to anti-angiogenic therapy in recurrent glioblastoma: amide proton transfer-weighted and perfusion-weighted MRI compared with diffusion-weighted MRI. Radiology 2020;295:397–406 doi:10.1148/radiol.2020191376 pmid:32154775

    CrossRefPubMed
18. 18.↵
    1. Zhang M,
    2. Gulotta B,
    3. Thomas A, et al

    . Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. Neuro Oncol 2016;18:735–43 doi:10.1093/neuonc/nov268 pmid:26538618

    CrossRefPubMed
19. 19.↵
    1. Page MJ,
    2. McKenzie JE,
    3. Bossuyt PM, et al

    . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71 doi:10.1136/bmj.n71 pmid:33782057

    FREE Full Text
20. 20.↵
    1. Whiting PF,
    2. Rutjes AW,
    3. Westwood ME, et al

    ; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36 doi:10.7326/0003-4819-155-8-201110180-00009 pmid:22007046

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Aquino D,
    2. Di Stefano AL,
    3. Scotti A, et al

    . Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan. PLoS One 2014;9:e90535 doi:10.1371/journal.pone.0090535 pmid:24675671

    CrossRefPubMed
22. 22.↵
    1. Harris RJ,
    2. Cloughesy TF,
    3. Hardy AJ, et al

    . MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2015;122:497–505 doi:10.1007/s11060-015-1755-8 pmid:25773062

    CrossRefPubMed
23. 23.↵
    1. Kickingereder P,
    2. Wiestler B,
    3. Burth S, et al

    . Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol 2015;17:1139–47 doi:10.1093/neuonc/nov028 pmid:25754089

    CrossRefPubMed
24. 24.↵
    1. Leu K,
    2. Enzmann DR,
    3. Woodworth DC, et al

    . Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. Cancer Imaging 2014;14:31 doi:10.1186/s40644-014-0031-z pmid:25608485

    CrossRefPubMed
25. 25.↵
    1. Wenger KJ,
    2. Hattingen E,
    3. Franz K, et al

    . Intracellular pH measured by 31 P-MR-spectroscopy might predict site of progression in recurrent glioblastoma under antiangiogenic therapy. J Magn Reson Imaging 2017;46:1200–08 doi:10.1002/jmri.25619 pmid:28165649

    CrossRefPubMed
26. 26.↵
    1. Hattingen E,
    2. Bähr O,
    3. Rieger J, et al

    . Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy. PLoS One 2013;8:e56439 doi:10.1371/journal.pone.0056439 pmid:23520454

    CrossRefPubMed
27. 27.↵
    1. Huang WY,
    2. Wen JB,
    3. Wu G, et al

    . Diffusion-weighted imaging for predicting and monitoring primary central nervous system lymphoma treatment response. AJNR Am J Neuroradiol 2016;37:2010–18 doi:10.3174/ajnr.A4867 pmid:27390318

    Abstract/FREE Full Text
28. 28.↵
    1. Plotkin SR,
    2. Stemmer-Rachamimov AO,
    3. Barker FG, 2nd., et al

    . Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358–67 doi:10.1056/NEJMoa0902579 pmid:19587327

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Wirsching HG,
    2. Roelcke U,
    3. Weller J, et al

    . MRI and ¹⁸FET-PET predict survival benefit from bevacizumab plus radiotherapy in patients with isocitrate dehydrogenase wild-type glioblastoma: results from the randomized ARTE trial. Clin Cancer Res 2021;27:179–88 doi:10.1158/1078-0432.CCR-20-2096 pmid:32967939

    Abstract/FREE Full Text
30. 30.↵
    1. Omuro A,
    2. Beal K,
    3. Gutin P, et al

    . Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res 2014;20:5023–31 doi:10.1158/1078-0432.CCR-14-0822 pmid:25107913

    Abstract/FREE Full Text
31. 31.↵
    1. Pope WB,
    2. Lai A,
    3. Mehta R, et al

    . Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 2011;32:882–89 doi:10.3174/ajnr.A2385 pmid:21330401

    Abstract/FREE Full Text
32. 32.↵
    1. Louis DN,
    2. Perry A,
    3. Wesseling P, et al

    . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

    CrossRefPubMed